Cadrenal Therapeutics, Inc. Common Stock

NasdaqCM CVKD

Cadrenal Therapeutics, Inc. Common Stock Free Cash Flow Yield on January 14, 2025

Cadrenal Therapeutics, Inc. Common Stock Free Cash Flow Yield is NA on January 14, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Cadrenal Therapeutics, Inc. Common Stock 52-week high Free Cash Flow Yield is -8.05% on January 31, 2024, which is NA below the current Free Cash Flow Yield.
Cadrenal Therapeutics, Inc. Common Stock 52-week low Free Cash Flow Yield is -42.19% on April 16, 2024, which is NA below the current Free Cash Flow Yield.
Cadrenal Therapeutics, Inc. Common Stock average Free Cash Flow Yield for the last 52 weeks is -28.17%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: CVKD

Cadrenal Therapeutics, Inc. Common Stock

CEO	Mr. Quang X. Pham
IPO Date	Jan. 20, 2023
Location	United States
Headquarters	822 A1A North
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key trends

Past 5 years